Open AccessA Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Author(s) -
Beata Holkova,
Adriana Zingone,
Maciej Kmieciak,
Prithviraj Bose,
Ashraf Badros,
Peter M. Voorhees,
Rachid Baz,
Neha Korde,
HuiYi Lin,
JinQiu Chen,
Michelle A. Herrmann,
Liqiang Xi,
Mark Raffeld,
Xiuhua Zhao,
Wen Wang,
Mary Beth Tombes,
Ellen Shrader,
Caryn Weir-Wiggins,
Heidi Sankala,
Kevin T. Hogan,
Austin E. Doyle,
Christina M. Annunziata,
Martha D. Wellons,
John D. Roberts,
Daniel M. Sullivan,
Ola Landgren,
Steven Grant
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/jba5-v347
Subject(s) - selumetinib , refractory (planetary science) , medicine , cancer research , oncology , biology , cancer , colorectal cancer , kras , astrobiology